These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

168 related articles for article (PubMed ID: 30537944)

  • 1. Use of predicted vital status to improve survival analysis of multidrug-resistant tuberculosis cohorts.
    Brooks MB; Keshavjee S; Gelmanova I; Zemlyanaya NA; Mitnick CD; Manjourides J
    BMC Med Res Methodol; 2018 Dec; 18(1):166. PubMed ID: 30537944
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of censoring assumptions to reduce bias in tuberculosis treatment cohort analyses.
    Brooks MB; Mitnick CD; Manjourides J
    PLoS One; 2020; 15(10):e0240297. PubMed ID: 33075072
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Survival of smear-positive multidrug resistant tuberculosis patients in Witbank, South Africa: A retrospective cohort study.
    Olaleye AO; Beke AK
    Infect Dis (Lond); 2016; 48(6):422-7. PubMed ID: 26954520
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Treatment outcomes in patients with multidrug-resistant tuberculosis in north-west Ethiopia.
    Alene KA; Viney K; McBryde ES; Tsegaye AT; Clements AC
    Trop Med Int Health; 2017 Mar; 22(3):351-362. PubMed ID: 27978594
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Survival time and influencing factors in multidrug-resistant tuberculosis patients in Wuhan, 2006-2014].
    Wang JJ; Zhou ML; Chen C; Wu G; Zuo YP; Ren X; Chen Z; Wang WH
    Zhonghua Liu Xing Bing Xue Za Zhi; 2019 Nov; 40(11):1409-1413. PubMed ID: 31838813
    [No Abstract]   [Full Text] [Related]  

  • 6. Treatment outcome of multidrug-resistant Mycobacterium tuberculosis in Nepal.
    Kakchapati S; Gyawali BN; Jha RK; Choonpradub C
    Asia Pac J Public Health; 2012 Jul; 24(4):631-40. PubMed ID: 22652251
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Comparison of the validity of smear and culture conversion as a prognostic marker of treatment outcome in patients with multidrug-resistant tuberculosis.
    Alene KA; Viney K; Yi H; McBryde ES; Yang K; Bai L; Gray DJ; Xu Z; Clements ACA
    PLoS One; 2018; 13(5):e0197880. PubMed ID: 29791488
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Validity of Time to Sputum Culture Conversion to Predict Cure in Patients with Multidrug-Resistant Tuberculosis: A Retrospective Single-Center Study.
    Javaid A; Ahmad N; Afridi AK; Basit A; Khan AH; Ahmad I; Atif M
    Am J Trop Med Hyg; 2018 Jun; 98(6):1629-1636. PubMed ID: 29611497
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The effect size of type 2 diabetes mellitus on tuberculosis drug resistance and adverse treatment outcomes.
    Perez-Navarro LM; Restrepo BI; Fuentes-Dominguez FJ; Duggirala R; Morales-Romero J; López-Alvarenga JC; Comas I; Zenteno-Cuevas R
    Tuberculosis (Edinb); 2017 Mar; 103():83-91. PubMed ID: 28237037
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Two-stage estimation to adjust for treatment switching in randomised trials: a simulation study investigating the use of inverse probability weighting instead of re-censoring.
    Latimer NR; Abrams KR; Siebert U
    BMC Med Res Methodol; 2019 Mar; 19(1):69. PubMed ID: 30935369
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Augmenting the logrank test in the design of clinical trials in which non-proportional hazards of the treatment effect may be anticipated.
    Royston P; Parmar MK
    BMC Med Res Methodol; 2016 Feb; 16():16. PubMed ID: 26869168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Delamanid, linezolid, levofloxacin, and pyrazinamide for the treatment of patients with fluoroquinolone-sensitive multidrug-resistant tuberculosis (Treatment Shortening of MDR-TB Using Existing and New Drugs, MDR-END): study protocol for a phase II/III, multicenter, randomized, open-label clinical trial.
    Lee M; Mok J; Kim DK; Shim TS; Koh WJ; Jeon D; Lee T; Lee SH; Kim JS; Park JS; Lee JY; Kim SY; Lee JH; Jo KW; Jhun BW; Kang YA; Ahn JH; Kim CK; Shin S; Song T; Shin SJ; Kim YR; Ahn H; Hahn S; Won HJ; Jang JY; Cho SN; Yim JJ
    Trials; 2019 Jan; 20(1):57. PubMed ID: 30651149
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Body mass index predictive of sputum culture conversion among MDR-TB patients in Indonesia.
    Putri FA; Burhan E; Nawas A; Soepandi PZ; Sutoyo DK; Agustin H; Isbaniah F; Dowdy DW
    Int J Tuberc Lung Dis; 2014 May; 18(5):564-70. PubMed ID: 24903794
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predictors and mortality associated with treatment default in pulmonary tuberculosis.
    Kliiman K; Altraja A
    Int J Tuberc Lung Dis; 2010 Apr; 14(4):454-63. PubMed ID: 20202304
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors and outcome of multidrug-resistant tuberculosis.
    Salomon N; Perlman DC; Friedmann P; Buchstein S; Kreiswirth BN; Mildvan D
    Clin Infect Dis; 1995 Nov; 21(5):1245-52. PubMed ID: 8589150
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic factors for treatment success in patients with multidrug-resistant tuberculosis in China.
    Fan YM; Ding SP; Bao ZJ; Wu LM; Zhen LB; Xia Q; Zhu M
    Int J Tuberc Lung Dis; 2018 Mar; 22(3):300-305. PubMed ID: 29471908
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Estimating the global burden of multidrug-resistant tuberculosis among prevalent cases of tuberculosis.
    Nourzad S; Jenkins HE; Milstein M; Mitnick CD
    Int J Tuberc Lung Dis; 2017 Jan; 21(1):6-11. PubMed ID: 28157458
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Comparison of methods for early-readmission prediction in a high-dimensional heterogeneous covariates and time-to-event outcome framework.
    Bussy S; Veil R; Looten V; Burgun A; Gaïffas S; Guilloux A; Ranque B; Jannot AS
    BMC Med Res Methodol; 2019 Mar; 19(1):50. PubMed ID: 30841867
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [The long term (9-year) survival of multidrug-resistant tuberculosis patients compared to non-multidrug-resistant tuberculosis patients in Henan province].
    Sun YN; Wang GJ; Zhen XA; Liu ZF; Harley D; Hall G; Vally H; Sleigh A
    Zhonghua Liu Xing Bing Xue Za Zhi; 2013 Feb; 34(2):133-6. PubMed ID: 23751466
    [TBL] [Abstract][Full Text] [Related]  

  • 20. HIV-positive patients treated for multidrug-resistant tuberculosis: clinical outcomes in the HAART era.
    Palacios E; Franke M; Muñoz M; Hurtado R; Dallman R; Chalco K; Guerra D; Mestanza L; Llaro K; Bonilla C; Sebastian J; Bayona J; Lygizos M; Anger H; Shin S
    Int J Tuberc Lung Dis; 2012; 16(3):348-54. PubMed ID: 22640448
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.